Tech Company Financing Transactions
Rhythm Pharmaceuticals Funding Round
Rhythm Pharmaceuticals closed a $8 million Series B funding round on 11/27/2012. Backers included Pfizer Venture Investments.
Transaction Overview
Company Name
Announced On
11/27/2012
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series B
Investors
Pfizer Venture Investments (Barbara Dalton)
Proceeds Purpose
Rhythm will use the proceeds to further develop its small-peptide therapeutics for metabolic diseases.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
222 Berkeley St. 12th Floor
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Website
Email Address
Overview
Rhythm (NASDAQ: RYTM) is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Meeker
Chief Financial Officer
Hunter Smith
Chief Medical Officer
Murray Stewart
Executive Vice President
Jennifer Chien
Executive Vice President
Yann Mazabraud
VP - Human Resources
Simon Kelner
Browse more venture capital transactions:
Prev: 11/27/2012: ClearCare venture capital transaction
Next: 11/27/2012: Whimseybox venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs